Reinfections by SARS-CoV2 virus in Santiago de Cuba province
Abstract
Introduction: The first cases of SARS-CoV-2 reinfections happened between March and August, 2020 in Belgium, EE. UU., Ecuador, India and China, with an interval between the first and second infection of 48 and 142 days, prevailing symptomatic forms.
Objective: To characterize patients with SARS-CoV-2 reinfections from Santiago de Cuba province.
Methods: An analytic and prospective observational study was carried out, whose population was conformed with the 122 cases of COVID-19 reinfection in the province from March, 2020 to September, 2021. The variables were sex, age group, municipality, occupation, time until reinfection measured once, clinical form, source of infection, stay, month of occurrence, measured at two times corresponding to each infection. Hypothesis tests were used to test the difference in means or proportions and associations between variables.
Results: The reinfections rate was 0.22%, with a significantly higher proportion of females. The average age was 43 years with prevalence between 20 and 59 years. The average time of reinfection was 139 days. The health workers prevailed (22.1%). The highest number of reinfections occurred in July and August, 2021.
Conclusions: A low rate of reinfections, similar to that reported in the literature, with an increase parallel to the circulation of new strains in the territory and a decrease in the asymptomatic clinical form, was characteristic of the province.
Downloads
References
2. Baruah V, Bose S. Immunoinformatics‐aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019‐nCoV. J Med Virol. 2020;92(5):495‐500.
3. Tan YJ, Goh PY, Fielding BC, Shen S, Chou CF, Fu JL, et al. Profiles of antibody Responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. Clin Diagn Lab Immunol. (2004) 11:362–71.
4. Wu HS, Hsieh YC, Su IJ, Lin TH, Chiu SC, Hsu YF, et al.Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients. JBiomed Sci. (2004) 11:117–26.
5. Centro Europeo para la Prevención y el Control de Enfermedades. Reinfección por SARS-CoV-2: consideraciones para la respuesta de salud pública: ECDC; 2020. Disponible en: https://bit.ly/31B9et3
6. Organización Panamericana de la Salud / Organización Mundial de la Salud. Orientaciones provisionales para la detección de casos de reinfección por el virus SARS CoV-2, 29 de octubre de 2020, Washington, D.C. OPS/OMS. 2020
7. Overbaugh, J. Understanding protection from SARS-CoV-2 by studying reinfection. Nat Med 26, 1680–1681 (2020). https://doi.org/10.1038/s41591-020-1121-z
8. Christian Holm Hansen*, Daniela Michlmayr*, Sophie Madeleine Gubbels, Kåre Mølbak, Steen Ethelberg.: “Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study”. Lancet 2021; 397: 1204–12.
9. Qureshi AI; Basket WI; Huan W; Lobanova I; Naqvi SH;Shyu ChR.: Re-infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) in patients undergoing serial laboratory testing.. Clinical Infectious Diseases® 2021 XX (XX): 1-7
10. Abu-Raddad L, Chemaitelly H, Malek JA, Ahmed AA, et al Assessment of the risk of severe acute respiratory syndrome coronavirus (SARS-CoV-2) reinfection in an intense re-exposure setting. MedRxiv 2020. https://doi.org/10.11 01/2020.08.24.20179457
11. Sagaró-del-Campo NM, Zamora-Matamoros L, Valdés-García LE, Rodríguez-Valdés A, Bandera-Jiménez D, Texidor-Garzón MC. Aspectos demográficos, clínico-epidemiológicos y geoespaciales de la COVID-19 en Santiago de Cuba. Archivo Médico Camagüey. 2021[acceso: 10/05/2021];25(3):391-404. Disponible en: http://www.revistaamc.sld.cu/index.php/amc/article/view/7979
12. Vitale J; Mumoli N; Clerici P, et al. Assessment of SARS-CoV-2 Re-infection 1 year after of Primary infection in population in Lombardy, Italy.. JAMA Intern Med. 2021;181(10):1407-1408
13. Bandera Jiménez D, Morandeira Padrón H, Valdés García LE, Rodríguez Valdés A, Sagaró Del Campo NM, Palú Orozco A, Romero Moya LI. Morbilidad por COVID-19: análisis de los aspectos epidemiológicos, clínicos y diagnósticos. Rev Cubana de Medicina Tropical. 2020;72(3):e574.
14. Contrera C,T; Mejias S, H: : Infeccion por SARS-CoV- 2 en personal de salud del Hospital del Niño Dr Ovidio Aliaga Uria. Rev. Med La Paz v.27 n.1 La Paz 2021. Versión On-line ISNN 1726-8958
15. Ong SWX, Chiew CJ, Ang LW, et al.: Clinical and Virological features of SARS-Cov-2 Variants of Concern: A restrospective Cohort Study comparing B.1.1.7 (Alpha), B1.3.1. (Beta) and B.1.617.2 (Delta)- SSRN
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 MEDISAN
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
